angiotensin ii, des-asp(1)-des-arg(2)-ile(5)- has been researched along with 1,3-dipropyl-8-cyclopentylxanthine in 1 studies
| Studies (angiotensin ii, des-asp(1)-des-arg(2)-ile(5)-) | Trials (angiotensin ii, des-asp(1)-des-arg(2)-ile(5)-) | Recent Studies (post-2010) (angiotensin ii, des-asp(1)-des-arg(2)-ile(5)-) | Studies (1,3-dipropyl-8-cyclopentylxanthine) | Trials (1,3-dipropyl-8-cyclopentylxanthine) | Recent Studies (post-2010) (1,3-dipropyl-8-cyclopentylxanthine) |
|---|---|---|---|---|---|
| 311 | 5 | 64 | 1,301 | 1 | 165 |
| Protein | Taxonomy | angiotensin ii, des-asp(1)-des-arg(2)-ile(5)- (IC50) | 1,3-dipropyl-8-cyclopentylxanthine (IC50) |
|---|---|---|---|
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | 0.0051 | |
| Adenosine receptor A3 | Rattus norvegicus (Norway rat) | 0.0038 | |
| Adenosine receptor A2a | Homo sapiens (human) | 0.2033 | |
| Adenosine receptor A2b | Homo sapiens (human) | 0.0234 | |
| Adenosine receptor A1 | Homo sapiens (human) | 0.0083 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Georgiev, V; Kambourova, T; Tchekalarova, J | 1 |
1 other study(ies) available for angiotensin ii, des-asp(1)-des-arg(2)-ile(5)- and 1,3-dipropyl-8-cyclopentylxanthine
| Article | Year |
|---|---|
Effects of angiotensin III and angiotensin IV on pentylenetetrazol seizure susceptibility (threshold and kindling): interaction with adenosine A(1) receptors.
Topics: Adenosine; Angiotensin II; Angiotensin III; Angiotensins; Animals; Brain; Convulsants; Disease Susceptibility; Dose-Response Relationship, Drug; Drug Interactions; Epilepsy; Kindling, Neurologic; Male; Mice; Mice, Inbred ICR; Pentylenetetrazole; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Receptors, Purinergic P1; Seizures; Xanthines | 2001 |